United Therapeutics Corporation (NASDAQ:UTHR) Given Average Recommendation of “Moderate Buy” by Brokerages

Posted by George Bondi on Jun 13th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $619.4167.

UTHR has been the topic of several recent analyst reports. Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a report on Thursday, May 7th. UBS Group upped their price target on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Bank of America upped their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Finally, HC Wainwright upped their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st.

Read Our Latest Report on UTHR

United Therapeutics Price Performance

UTHR opened at $545.96 on Monday. The stock has a market capitalization of $23.18 billion, a PE ratio of 20.15, a P/E/G ratio of 1.78 and a beta of 0.57. The firm’s fifty day moving average price is $566.75 and its 200 day moving average price is $521.34. United Therapeutics has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the company earned $6.63 earnings per share. On average, equities research analysts forecast that United Therapeutics will post 26.84 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $547.07, for a total transaction of $4,540,681.00. Following the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $24,712,246.04. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $549.29, for a total transaction of $5,492,900.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $10,368,398.04. This trade represents a 34.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 634,984 shares of company stock valued at $358,175,202. Company insiders own 8.60% of the company’s stock.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of UTHR. Wellington Management Group LLP raised its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Darwin Global Management Ltd. acquired a new stake in shares of United Therapeutics during the third quarter worth $317,617,000. Norges Bank acquired a new stake in shares of United Therapeutics during the fourth quarter worth $293,418,000. Avoro Capital Advisors LLC raised its holdings in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after purchasing an additional 383,838 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of United Therapeutics by 75.1% during the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.